Mustafa A. Arain, Rajeev Attam, Martin L. Freeman – 15 February 2013 – Biliary tract complications after liver transplantation (LT) most commonly include biliary leaks, strictures, and stone disease. Living donor recipients and donation after cardiac death recipients are at an increased risk of developing biliary complications. Biliary leaks usually occur early after transplantation, whereas strictures and stone disease occur later. The diagnosis of biliary complications relies on a combination of clinical presentation, laboratory abnormalities, and imaging modalities.

Phillipp Hartmann, Peng Chen, Hui J. Wang, Lirui Wang, Declan F. McCole, Katharina Brandl, Peter Stärkel, Clara Belzer, Claus Hellerbrand, Hidekazu Tsukamoto, Samuel B. Ho, Bernd Schnabl – 13 February 2013 – The intestinal mucus layer protects the epithelium from noxious agents, viruses, and pathogenic bacteria present in the gastrointestinal tract. It is composed of mucins, predominantly mucin (Muc) 2, secreted by goblet cells of the intestine.

Jun Yan, Changjun Tan, Fangming Gu, Jiahao Jiang, Min Xu, Xiuzhen Huang, Zhi Dai, Zheng Wang, Jia Fan, Jian Zhou – 13 February 2013 – Liver transplantation (LT) is one of the curative treatments for hepatocellular carcinoma (HCC). However, cancer recurrence and metastasis after LT are common in some HCC patients with high‐risk factors (even in those within the Milan criteria). It remains unclear whether adjuvant therapy with sorafenib inhibits HCC recurrence and metastasis after LT. Therefore, we performed orthotopic LT in an August Irish Copenhagen (ACI) rat model of HCC.

Lloyd Brown, Ahmad Abou Abbass, Shunji Nagai, Vrishali Patil, Marwan Abouljoud, Todd Getzen, Atsushi Yoshida, Marwan Kazimi, Dean Y. Kim – 13 February 2013

Filippo Schepis, Ranka Vukotic, Annalisa Berzigotti, José A. Carrión, Xavier Forns, Juan G. Abraldes, Juan‐Carlos García‐Valdecasas, Miguel Navasa, Juan‐Carlos García‐Pagán, Jaime Bosch – 13 February 2013 – Cirrhosis recurrence is frequent after orthotopic liver transplantation for hepatitis C virus (HCV). Because transplantation causes liver denervation, we hypothesized that the response to propranolol might differ in transplant patients versus nontransplant patients with cirrhosis and portal hypertension.

Mamatha Bhat, Nahum Sonenberg, Gregory J. Gores – 13 February 2013 – The mechanistic/mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular metabolism, growth, and proliferation and has been evaluated as a target for therapy in various malignancies. The mTOR pathway is a major tumor‐initiating pathway in hepatocellular carcinoma, with up‐regulation seen in up to 50% of tumors. Metformin, which represses mTOR signaling by activating adenosine monophosphate–activated protein kinase, has been shown to decrease liver carcinogenesis in population studies.

Li‐Na Zhang, Tian‐Yan Shi, Xu‐Hua Shi, Li Wang, Yun‐Jiao Yang, Bin Liu, Li‐Xia Gao, Zong‐Wen Shuai, Fang Kong, Hua Chen, Wei Han, Shao‐Mei Han, Yun‐Yun Fei, Quan‐Cai Cui, Qian Wang, Min Shen, Dong Xu, Wen‐Jie Zheng, Yong‐Zhe Li, Wen Zhang, Xuan Zhang, Feng‐Chun Zhang – 13 February 2013 – The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long‐term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches.

Jacqueline G. O'Leary, Gregory J. McKenna, Göran B. Klintmalm, Gary L. Davis – 13 February 2013

Abdul R. Hakeem, Andrew J. Cockbain, Syed S. Raza, Stephen G. Pollard, Giles J. Toogood, Magdy A. Attia, Niaz Ahmad, Ernest L. Hidalgo, K. Raj Prasad, Krishna V. Menon – 13 February 2013 – Obesity levels in the United Kingdom have risen over the years. Studies from the United States and elsewhere have reported variable outcomes for obese liver transplant recipients in terms of post–liver transplant morbidity, mortality, and graft survival. This study was designed to analyze the impact of the body mass index (BMI) on outcomes following adult liver transplantation.

Hasan Yersiz, Coney Lee, Fady M. Kaldas, Johnny C. Hong, Abbas Rana, Gabriel T. Schnickel, Jason A. Wertheim, Ali Zarrinpar, Vatche G. Agopian, Jeffrey Gornbein, Bita V. Naini, Charles R. Lassman, Ronald W. Busuttil, Henrik Petrowsky – 13 February 2013 – An accurate clinical assessment of hepatic steatosis before transplantation is critical for successful outcomes after liver transplantation, especially if a pathologist is not available at the time of procurement.